J
Jean-Christophe Lagier
Researcher at Aix-Marseille University
Publications - 311
Citations - 17625
Jean-Christophe Lagier is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Genome & Medicine. The author has an hindex of 50, co-authored 274 publications receiving 13861 citations. Previous affiliations of Jean-Christophe Lagier include Institut de recherche pour le développement & Centre national de la recherche scientifique.
Papers
More filters
Journal ArticleDOI
A polyphasic strategy incorporating genomic data for the taxonomic description of novel bacterial species
Dhamodharan Ramasamy,Ajay Kumar Mishra,Jean-Christophe Lagier,Roshan Padhmanabhan,Morgane Rossi,Erwin Sentausa,Didier Raoult,Pierre-Edouard Fournier +7 more
TL;DR: The pros and cons of genome sequencing for taxonomy are reviewed and it is proposed that the incorporation of genome sequences in taxonomic studies has the advantage of using reliable and reproducible data.
Journal ArticleDOI
Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths.
Paul Bastard,Adrian Gervais,Adrian Gervais,Tom Le Voyer,Tom Le Voyer,Jérémie Rosain,Jérémie Rosain,Quentin Philippot,Quentin Philippot,Jeremy Manry,Jeremy Manry,Eleftherios Michailidis,Hans-Heinrich Hoffmann,Shohei Eto,Marina Garcia-Prat,Lucy Bizien,Lucy Bizien,Alba Parra-Martínez,Rui Yang,Liis Haljasmägi,Mélanie Migaud,Mélanie Migaud,Karita Särekannu,Julia Maslovskaja,Nicolas de Prost,Yacine Tandjaoui-Lambiotte,Charles-Edouard Luyt,Charles-Edouard Luyt,Blanca Amador-Borrero,Alexandre Gaudet,Julien Poissy,Pascal Morel,Pascale Richard,Fabrice Cognasse,Jesús Troya,Sophie Trouillet-Assant,Alexandre Belot,Alexandre Belot,Kahina Saker,Pierre Garçon,Jacques G. Rivière,Jean-Christophe Lagier,Stéphanie Gentile,Lindsey B. Rosen,Elana Shaw,Tomohiro Morio,Junko Tanaka,David Dalmau,Pierre-Louis Tharaux,Damien Sène,Alain Stepanian,Bruno Mégarbane,Vasiliki Triantafyllia,Arnaud Fekkar,James R. Heath,José Luis Franco,Juan-Manuel Anaya,Jordi Solé-Violán,Luisa Imberti +58 more
TL;DR: In this paper, the authors found that auto-antibodies neutralizing high concentrations (10 ng/mL, in plasma diluted 1 to 10) of IFN-α and/or -ω are found in about 10% of patients with critical COVID-19 pneumonia, but not in subjects with asymptomatic infections.
Journal ArticleDOI
Human Gut Microbiota: Repertoire and Variations
TL;DR: A considerable limitation to the interpretation of studies of human gut microbiota is associated with funding sources and transparency disclosures, and studies independent of food industry funding and using complementary methods from a broad range of both culture-based and molecular tools will increase knowledge of the repertoire of this complex ecosystem and host-microbiota mutualism.
Journal ArticleDOI
Gut bacterial microbiota and obesity
TL;DR: The studies describing the associations between the microbiota composition, its manipulation, and obesity are reviewed to propose mechanisms linking the microbiota to fat content and weight.
Journal ArticleDOI
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis.
Jean-Christophe Lagier,Matthieu Million,Philippe Gautret,Philippe Colson,Sébastien Cortaredona,Audrey Giraud-Gatineau,Stéphane Honoré,Jean-Yves Gaubert,Pierre-Edouard Fournier,Hervé Tissot-Dupont,Eric Chabrière,Andreas Stein,Jean-Claude Deharo,Florence Fenollar,Jean-Marc Rolain,Yolande Obadia,Alexis Jacquier,Bernard La Scola,Philippe Brouqui,Michel Drancourt,Philippe Parola,Didier Raoult,Sophie Amrane,Camille Aubry,Matthieu Bardou,Cyril Berenger,Laurence Camoin-Jau,Nadim Cassir,Claire Decoster,Catherine Dhiver,Barbara Doudier,Sophie Edouard,Stéphanie Gentile,Katell Guillon-Lorvellec,Marie Hocquart,Anthony Levasseur,Morgane Mailhe,Isabelle Ravaux,Magali Richez,Yanis Roussel,Piseth Seng,Christelle Tomei,Christine Zandotti +42 more
TL;DR: Results suggest that early diagnosis, early isolation and early treatment of COVID-19 patients, with at least 3 days of HCQ-AZ lead to a significantly better clinical outcome and a faster viral load reduction than other treatments.